ZA200908592B - Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission - Google Patents

Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Info

Publication number
ZA200908592B
ZA200908592B ZA2009/08592A ZA200908592A ZA200908592B ZA 200908592 B ZA200908592 B ZA 200908592B ZA 2009/08592 A ZA2009/08592 A ZA 2009/08592A ZA 200908592 A ZA200908592 A ZA 200908592A ZA 200908592 B ZA200908592 B ZA 200908592B
Authority
ZA
South Africa
Prior art keywords
modulators
phenylpyrrolidines
disubstituted
cortical
catecholaminergic neurotransmission
Prior art date
Application number
ZA2009/08592A
Other languages
English (en)
Inventor
Susanna Waters
Fredrik Pettersson
Nicholas Waters
Lars Swanson
Clas Sonesson
Original Assignee
Nsab Filial Af Neurosearch Sweden Ab Sverige
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab Filial Af Neurosearch Sweden Ab Sverige filed Critical Nsab Filial Af Neurosearch Sweden Ab Sverige
Publication of ZA200908592B publication Critical patent/ZA200908592B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2009/08592A 2007-06-05 2009-12-03 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission ZA200908592B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0701387 2007-06-05
PCT/EP2008/056915 WO2008148801A2 (en) 2007-06-05 2008-06-04 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Publications (1)

Publication Number Publication Date
ZA200908592B true ZA200908592B (en) 2011-02-23

Family

ID=39743744

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2009/08592A ZA200908592B (en) 2007-06-05 2009-12-03 Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Country Status (16)

Country Link
US (1) US8188301B2 (enExample)
EP (1) EP2155671B8 (enExample)
JP (1) JP5444535B2 (enExample)
KR (1) KR20100038295A (enExample)
CN (1) CN101808987A (enExample)
AU (1) AU2008258599B2 (enExample)
BR (1) BRPI0812740A2 (enExample)
CA (1) CA2690091A1 (enExample)
CO (1) CO6251288A2 (enExample)
IL (1) IL202045A0 (enExample)
MX (1) MX2009012787A (enExample)
NZ (1) NZ581364A (enExample)
RU (1) RU2471781C2 (enExample)
UA (1) UA98783C2 (enExample)
WO (1) WO2008148801A2 (enExample)
ZA (1) ZA200908592B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155671B8 (en) 2007-06-05 2018-02-21 Integrative Research Laboratories Sweden AB Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP2367787B1 (en) 2008-11-24 2013-01-09 NSAB, Filial af NeuroSearch Sweden AB, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
US20110257148A1 (en) * 2008-11-24 2011-10-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
WO2010058017A1 (en) 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
AR074755A1 (es) * 2008-12-16 2011-02-09 Astrazeneca Ab Derivados cuaternarios de piperidina y sus usos
WO2011005761A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc Novel nucleic acid prodrugs and methods use thereof
WO2012039448A1 (ja) * 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
AU2013288048A1 (en) 2012-07-13 2015-01-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN113278617A (zh) 2014-01-16 2021-08-20 波涛生命科学有限公司 手性设计
EP3297987B1 (en) * 2015-05-20 2019-05-15 Integrative Research Laboratories Sweden AB Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission
CN108698989B (zh) 2016-02-10 2021-05-11 住友化学株式会社 用于制备1-甲基吡咯烷-3-醇的方法
CA3064136A1 (en) * 2017-05-19 2018-11-22 Integrative Research Laboratories Sweden Ab (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878264A (en) * 1959-03-17 Substituted amino alcohols
CH372667A (de) 1957-09-26 1963-10-31 Robins Co Inc A H Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
US3118907A (en) * 1961-08-14 1964-01-21 Mead Johnson & Co 3-substituted-3-pyrrolidinols
BE704683A (enExample) 1966-11-07 1968-02-15
US3647790A (en) * 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
US5128362A (en) * 1988-01-15 1992-07-07 Abbott Laboratories 1-aminomethyl-1,2,3,4-tetrahydronaphthalenes
DE3802175A1 (de) 1988-01-26 1989-08-03 Hoechst Ag N-phenylbenzamide und n-phenylbenzamidoxime, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als schaedlingsbekaempfungsmittel
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
US5444083A (en) * 1989-02-03 1995-08-22 Eisai Co., Ltd. Pyrrolidine compound and pharmaceutical use
EP0641320B1 (en) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
HUP0102622A3 (en) 1998-07-20 2002-12-28 Merck Patent Gmbh Biphenyl derivatives, process for producing them and pharmaceutical compositions containing them
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
DE19840611A1 (de) * 1998-09-05 2000-03-09 Klaus Wanner GABA-uptake-Inhibitoren mit Pyrrolidinstruktur
AU5025600A (en) 1999-05-17 2000-12-05 Foxboro Company, The Process control configuration system with parameterized objects
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7700587B2 (en) * 2004-09-07 2010-04-20 Florida A&M University Haloperidol analogs
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP1879863A1 (en) 2005-05-03 2008-01-23 Pfizer, Inc. Amide resorcinol compounds
WO2007053145A1 (en) 2005-11-04 2007-05-10 Florida A & M University Haloperidol analogs
CA2626220A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
EP2155671B8 (en) 2007-06-05 2018-02-21 Integrative Research Laboratories Sweden AB Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
US20100197760A1 (en) 2007-06-05 2010-08-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission

Also Published As

Publication number Publication date
WO2008148801A3 (en) 2009-01-29
WO2008148801A2 (en) 2008-12-11
JP2010529081A (ja) 2010-08-26
KR20100038295A (ko) 2010-04-14
AU2008258599B2 (en) 2013-06-13
AU2008258599A1 (en) 2008-12-11
EP2155671B1 (en) 2017-12-20
CN101808987A (zh) 2010-08-18
CA2690091A1 (en) 2008-12-11
JP5444535B2 (ja) 2014-03-19
EP2155671B8 (en) 2018-02-21
CO6251288A2 (es) 2011-02-21
US8188301B2 (en) 2012-05-29
NZ581364A (en) 2011-10-28
UA98783C2 (en) 2012-06-25
IL202045A0 (en) 2010-06-16
WO2008148801A8 (en) 2009-12-10
RU2471781C2 (ru) 2013-01-10
BRPI0812740A2 (pt) 2016-07-19
MX2009012787A (es) 2009-12-15
RU2009143104A (ru) 2011-07-20
EP2155671A2 (en) 2010-02-24
US20100179211A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
ZA200908592B (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
IL219192A0 (en) Novel modulators of calcium release-activated calcium channel
IL219585A (en) Compounds 4h - Novel-4 - On as modulators of kinase proteins
ZA201007677B (en) Quenolines and related analogs as sirtuin modulators
ZA201102674B (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
EP2370956A4 (en) DYNAMIC DETAIL LEVEL
ZA201200842B (en) Methods of using c-met modulators
EP2229939A4 (en) CAPSULE FORMULATION
EP2373645A4 (en) ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS
IL219926A0 (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
ZA201008076B (en) Calibration of dtonators
GB0818822D0 (en) Reduction of stray light
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
ZA201006932B (en) Modulators of dopamine neurotransmission
EP2231687A4 (en) NEW DERIVATIVES OF ACYL-CYANPYRROLIDINES
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
ZA201103169B (en) 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
EP2328873A4 (en) PREPARATION OF RANOLAZINE
HUE037655T2 (hu) Egy észteráz elõállítása
IL199765A0 (en) Use of tocopherol
EP2358693A4 (en) PREPARATION OF DOCETAXEL
TWI367205B (en) Preparation of paricalcitol
IL207045A0 (en) Solid forms of ortataxel
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
UA17835S (uk) Блок контейнерів на стоматологічні потреби